{"id":61425,"date":"2026-03-26T16:40:10","date_gmt":"2026-03-26T08:40:10","guid":{"rendered":"https:\/\/flcube.com\/?p=61425"},"modified":"2026-03-26T16:40:11","modified_gmt":"2026-03-26T08:40:11","slug":"simcere-pharma-2025-revenue-rmb-7-7b-innovative-drugs-drive-28-growth-profit-surges-86","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=61425","title":{"rendered":"Simcere Pharma 2025 Revenue RMB 7.7B \u2013 Innovative Drugs Drive 28% Growth, Profit Surges 86%"},"content":{"rendered":"\n

Simcere Pharmaceutical Group<\/strong> (HKG: 2096<\/a>) reported 2025 financial results<\/strong>, with revenue rising 16.5% YoY to RMB 7.7 billion (USD 1.1 billion)<\/strong>. Innovative drug business surged 27.9% to RMB 6.304 billion (USD 913 million)<\/strong>, driving profits attributable to shareholders up 86.2% to RMB 1.344 billion (USD 194 million)<\/strong>. The company launched two new innovative products<\/strong> \u2013 Quviviq (daridorexan) for insomnia<\/strong> and Enzeshu (suvemcitug) for platinum-resistant ovarian cancer<\/strong> \u2013 expanding its neuroscience and oncology franchises<\/strong>.<\/p>\n\n\n\n

Financial Highlights<\/h2>\n\n\n\n
Metric<\/th>2025 Result<\/th>YoY Change<\/th>Strategic Driver<\/th><\/tr><\/thead>
Total Revenue<\/strong><\/td>RMB 7.7B (USD 1.1B)<\/td>+16.5%<\/td>Innovative drug momentum + new product launches<\/td><\/tr>
Innovative Drug Revenue<\/strong><\/td>RMB 6.304B (USD 913M)<\/td>+27.9%<\/strong><\/td>81.9% of total revenue<\/strong> \u2013 transformation complete<\/td><\/tr>
Profit Attributable<\/strong><\/td>RMB 1.344B (USD 194M)<\/td>+86.2%<\/strong><\/td>Operating leverage + high-margin innovation mix<\/td><\/tr>
Neuroscience<\/strong><\/td>RMB 2.753B (USD 398M)<\/td>+26.6%<\/td>Core franchise strength<\/td><\/tr>
Autoimmune<\/strong><\/td>RMB 1.892B (USD 274M)<\/td>+4.5%<\/td>Stable contribution<\/td><\/tr>
Oncology<\/strong><\/td>RMB 1.987B (USD 287M)<\/td>+53.0%<\/strong><\/td>Fastest-growing segment<\/strong> \u2013 Enzeshu launch impact<\/td><\/tr>
Other<\/strong><\/td>RMB 1.099B (USD 159M)<\/td>-18.7%<\/td>Portfolio rationalization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

2025 New Product Launches<\/h2>\n\n\n\n
Product<\/th>Indication<\/th>Differentiation<\/th>Launch Impact<\/th><\/tr><\/thead>
Quviviq<\/strong> (daridorexan)<\/td>Adult insomnia<\/strong> (sleep onset\/maintenance)<\/td>Non-controlled substance<\/strong> (Schedule IV exempt) \u2013 addresses abuse liability concerns vs. zolpidem<\/td>Neuroscience expansion<\/strong> \u2013 RMB 500M+ peak potential<\/td><\/tr>
Enzeshu<\/strong> (suvemcitug)<\/td>Platinum-resistant ovarian\/fallopian tube\/peritoneal cancer<\/strong><\/td>Combination with paclitaxel, doxorubicin liposomes, or topotecan<\/strong>; \u22641 prior systemic therapy<\/strong> positioning<\/td>Oncology 53% growth driver<\/strong>; addresses high unmet need in recurrent disease<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Strategic Context: Therapeutic Area Performance<\/h2>\n\n\n\n
Segment<\/th>Revenue<\/th>Growth<\/th>Key Assets<\/th>Strategic Priority<\/th><\/tr><\/thead>
Neuroscience<\/strong><\/td>RMB 2.753B<\/td>+26.6%<\/td>Mustard<\/strong> (edible bird’s nest extract), Quviviq<\/strong> launch<\/td>Core franchise<\/strong> \u2013 largest revenue base; insomnia addition<\/td><\/tr>
Oncology<\/strong><\/td>RMB 1.987B<\/td>+53.0%<\/strong><\/td>Enzeshu<\/strong> launch, Endostar<\/strong> (rh-endostatin)<\/td>High-growth engine<\/strong> \u2013 targeted therapies + immuno-oncology<\/td><\/tr>
Autoimmune<\/strong><\/td>RMB 1.892B<\/td>+4.5%<\/td>Xinmei<\/strong> (triptolide), Iremod<\/strong> (iguratimod)<\/td>Stable cash flow<\/strong> \u2013 established RA\/lupus positioning<\/td><\/tr>
Other<\/strong><\/td>RMB 1.099B<\/td>-18.7%<\/td>Legacy products<\/td>Portfolio optimization<\/strong> \u2013 divestment of non-core assets<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding 2026 revenue growth, Quviviq\/Enzeshu market penetration, and therapeutic area expansion. Actual results may differ due to competitive dynamics in insomnia (lemborexant, daridorexan) and ovarian cancer (PARP inhibitors, bevacizumab), and NRDL negotiation outcomes for new products.-Fineline Info & Tech<\/a><\/p>\n\n\n\n